Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Caen
Clinical trial register · France

Clinical Trials in Caen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9698 matching records held by the registry are in this view. Synced 23 Oct 2026, 03:20 UTC
9698
Studies in scope
all four open statuses
6023
Recruiting now
open to new participants
1034
Lead sponsors
across recruiting studies
Top sites
Bordeaux 40 Caen 36 Angers 31 Dijon 30 Avignon 27
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital, Caen53 UNICANCER36 Centre Francois Baclesse32 AstraZeneca30 Assistance Publique - Hôpitaux de Paris23 Clear sponsor filter
Site location
Bordeaux40 Caen36 Angers31 Dijon30 Avignon27
All 80 locations
Target enrolment
to

Trials with a site in Caen

36 of 9698 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Not yet open
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer
NCT07241273Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers, Oropharyngeal Carcinoma, Head and Neck
UNICANCER
Not applicable
128
Brest, Caen, Dijon, Le Havre, Lille, Montpellier, Paris, Rouen
2026-09
Not yet open
UNICANCER
Phase 2
130
Auxerre, Beuvry, Caen, Calais, Compiègne, Coudekerque-Branche, Lille, Lyon
2026-08-31
Not yet open
UNICANCER
Phase 2/3
160
Angers, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille
2026-07
Recruiting
UNICANCER
Phase 2
72
Amiens, Angers, Avignon, Besançon, Bordeaux, Caen, Clermont-Ferrand, Clichy
2025-10-09
Recruiting
UNICANCER
Not applicable
724
Arras, Beuvry, Bordeaux, Caen, Chambray-lès-Tours, Clermont-Ferrand, Créteil, Dechy
2025-10-07
Recruiting
UNICANCER
Phase 2
220
Amiens, Avignon, Bayonne, Besançon, Bordeaux, Caen, Dijon, La Roche-sur-Yon
2025-03-11
Recruiting
UNICANCER
Phase 2
198
Angers, Besançon, Bordeaux, Caen, Clermont-Ferrand, Dijon, Limoges, Lyon
2025-01-27
Recruiting
UNICANCER
Phase 2
400
Amiens, Aurillac, Avignon, Bayeux, Bayonne, Besançon, Caen, Caluire-et-Cuire
2025-01-20
Recruiting
UNICANCER
Phase 2
354
Amiens, Avignon, Bayonne, Bordeaux, Caen, Clermont-Ferrand, Dijon, Levallois-Perret
2024-12-27
Recruiting
UNICANCER
Phase 3
500
Angers, Bordeaux, Brest, Caen, Créteil, Dijon, Grenoble, Lyon
2024-09-12
Recruiting
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
NCT06333314Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma
DrugDostarlimab
UNICANCER
Phase 2
120
Angers, Avignon, Besançon, Brest, Caen, Clermont-Ferrand, Créteil, Dijon
2024-07-23
Recruiting
UNICANCER
Phase 3
800
Amiens, Angers, Avignon, Besançon, Bordeaux, Caen, Clermont-Ferrand, Créteil
2024-07-18
Recruiting
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
NCT05800275Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer
DrugsTucatinib·Trastuzumab·Capecitabine
UNICANCER
Phase 2
30
Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Montpellier, Nice, Reims
2023-12-18
Active, closed
UNICANCER
Phase 2
100
Aix-en-Provence, Avignon, Bayonne, Caen, Clermont-Ferrand, Créteil, Dijon, Lille
2023-03-24
Active, closed
UNICANCER
Phase 2
10
Bobigny, Bordeaux, Boulogne-Billancourt, Caen, Créteil, Dijon, Lyon, Marseille
2022-09-05
Recruiting
UNICANCER
Phase 3
300
Avignon, Bayonne, Besançon, Beuvry, Bordeaux, Brest, Caen, Chambéry
2022-04-19
Active, closed
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
NCT05078047Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
UNICANCER
Phase 3
646
Angers, Avignon, Bayonne, Bordeaux, Boulogne-sur-Mer, Caen, Clermont-Ferrand, Créteil
2022-03-08
Active, closed
UNICANCER
Phase 2
53
Angers, Bordeaux, Caen, Dijon, Le Mans, Lyon, Montpellier, Nice
2021-12-17
Recruiting
UNICANCER
Phase 3
102
Avignon, Besançon, Bordeaux, Caen, Carcassonne, Clermont-Ferrand, Dijon, Le Havre
2021-12-01
Active, closed
UNICANCER
Phase 3
550
Avignon, Bordeaux, Brest, Caen, Clermont-Ferrand, Creil, Créteil, Jossigny
2020-06-23
Active, closed
UNICANCER
Not applicable
200
Angers, Avignon, Caen, Chalon-sur-Saône, Cholet, Clermont-Ferrand, Dijon, Lyon
2019-10-23
Active, closed
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast
NCT03878342DCIS, Breast Cancer, Low Risk DCIS, Breast Conserving Surgery
UNICANCER
Not applicable
295
Angers, Avignon, Bayonne, Bordeaux, Caen, Cherbourg, Clermont-Ferrand, Créteil
2019-05-10
Active, closed
UNICANCER
Phase 2
60
Amiens, Angers, Bordeaux, Caen, La Tronche, Lille, Lyon, Marseille
2018-10-23
Active, closed
Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence
NCT03438552Local Recurrence of Malignant Tumor of Prostate
UNICANCER
Not applicable
57
Caen, Clermont-Ferrand, Dijon, Lille, Lyon, Montpellier, Paris, Rennes
2018-10-18
Active, closed
UNICANCER
Not applicable
81
Angers, Bordeaux, Caen, Dijon, Grenoble, Lille, Limoges, Lorient
2018-04-19
Active, closed
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03774732Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
DrugPembrolizumab
UNICANCER
Phase 3
327
Angers, Arras, Avignon, Beuvry, Blois, Bordeaux, Brest, Caen
2018-01-24
Recruiting
UNICANCER
Observational
75,000
Angers, Bordeaux, Caen, Clermont-Ferrand, Créteil, Dijon, Lille, Lyon
2017-10-02
Active, closed
QUALIOR Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program
NCT03169075Home Based Standardised Adapted Physical Activity Programme, Patients Taking Oral Targeted Therapy for Metastatic Cancer
UNICANCER
Not applicable
190
Angers, Annecy, Besançon, Caen, Cholet, Grenoble, La Roche-sur-Yon, Lyon
2017-07-11
Active, closed
UNICANCER
Phase 2
37
Angers, Besançon, Bordeaux, Caen, Clermont-Ferrand, Limoges, Lyon, Marseille
2016-10-17
Recruiting
UNICANCER
Observational
42,000
Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille
2014-07
Active, closed
UNICANCER
Phase 2
1,460
Angers, Avignon, Bordeaux, Caen, Clermont-Ferrand, Dijon, La Roche-sur-Yon, Lille
2014-04-07
Active, closed
UNICANCER
Phase 2
120
Angers, Avignon, Besançon, Bordeaux, Brest, Caen, Chambéry, Créteil
2012-12
Active, closed
UNICANCER
Phase 3
415
Amiens, Angers, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon, Grenoble
2011-04-26
Active, closed
UNICANCER
Not applicable
1,006
Amiens, Bordeaux, Brivé, Caen, Chambéry, Créteil, Dechy, Grenoble
2010-12-27
Active, closed
UNICANCER
Not applicable
500
Angers, Bordeaux, Caen, Chambéry, Chambray-lès-Tours, Créteil, Lyon, Marseille
2008-10
Active, closed
UNICANCER
Phase 3
318
Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon, Grenoble
2007-03
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-france/city/caen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,698 studies in total at the last sync on 23 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Caen that also match the filters currently applied.

How many clinical trials are recruiting in Caen?

14 of the 36 studies on this page are recruiting new participants as of the 23 Oct 2026, 03:20 UTC sync. A further 3 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Caen), 36 studies
PhaseStudiesRecruitingShare
Phase 215741.7%
Not applicable9125%
Phase 39425%
Observational225.6%
Phase 2/3102.8%

Most active sponsors

Lead sponsors with the most studies (Caen)
Lead sponsorStudiesRecruiting
UNICANCER3614
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.